BioLamina

Executive Summary

BioLamina is a Swedish biotechnology company specializing in the development and supply of human recombinant laminin cell culture matrices. Founded in 2008 and headquartered in Sundbyberg, the company offers a range of animal-origin-free, biologically relevant substrates under the Biolaminin® brand for both 2D and 3D cell culture applications. With a focus on enabling robust and clinically compliant cell culture processes, BioLamina serves the research, drug discovery, and cell therapy sectors. The company's products are critical for maintaining stem cell pluripotency and differentiation, addressing the growing need for defined, scalable culture systems in regenerative medicine and cell therapy manufacturing. By eliminating animal-derived components, BioLamina supports the production of safer, more reproducible therapeutic cells.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation Biolaminin for 3D organoid culture80% success
• Q4 2026Strategic partnership with a leading cell therapy developer for GMP-grade laminin supply65% success
• Q1 2027Regulatory approval for use in a clinical-stage CAR-T therapy50% success